Semaglutide associated with lower risk of suicidal ideations compared to other treatments prescribed for obesity or type 2 diabetes

NIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medication [] [View as webpage / Share]( [NIH/NIDA logo] NEWS [Woman sitting at home at a table working on her laptop and smiling while her pre-teen son hugs her. ] Semaglutide associated with lower risk of suicidal ideations compared to other treatments prescribed for obesity or type 2 diabetes Semaglutide, a highly popular medication approved by the U.S. Food and Drug Administration to treat obesity and manage type 2 diabetes, was associated with a 49% to 73% lower risk of first-time or recurring suicidal ideations compared to other medications for controlling obesity and type 2 diabetes that work via different mechanisms. These findings provide evidence that semaglutide – which helps regulate appetite and insulin levels by targeting glucagon-like peptide 1 receptors (GLP1R) in the body – does not appear to increase the risk of suicidal ideation, contrary to the claims of some anecdotal reports. Published today in Nature Medicine and paired with [a related Research Briefing](, [the study]( was co-led by scientists at Case Western Reserve University and the National Institute on Drug Abuse, National Institutes of Health. [View the Media Advisory]( Stay Connected [facebook]([twitter]([linkedin]([youtube]( --------------------------------------------------------------- View topics of interest, update your subscriptions, modify your password or email address, alter frequency of bulletins, or stop subscriptions at any time on your [Subscriber Preferences Page](. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit [subscriberhelp.govdelivery.com](. This service is provided to you at no charge by [National Institute on Drug Abuse](. --------------------------------------------------------------- This email was sent to {EMAIL} using govDelivery Communications Cloud on behalf of National Institutes of Health: National Institute on Drug Abuse · 3WFN MSC 6024 · 16071 Industrial Dr ·Dock 11 · Gaithersburg, MD 20877 [GovDelivery logo](